Publication | Closed Access

Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma

OncologyMedicineMelanomaPhase Ii StudyDual Antiangiogenic InhibitionAdvanced Malignant MelanomaPharmacotherapyAnti-cancer AgentDermatologyCancer TreatmentPharmacology